Previous 10 | Next 10 |
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
RAMSEY, N.J. and BOCA RATON, Fla., July 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops s...
There are several reasons biotechnology stocks are an investor favorite. One of those reasons is that this is a vast sector. Here, companies great and small develop the next generation of treatments and medical advancements that cover everything from chronic illness to cosmetic enhan...
The following slide deck was published by ADMA Biologics, Inc. in conjunction with this Read more ...
Introduction Every year the Russell Indexes are rebalanced to bring in new stocks and remove underperforming stocks. The FTSE Russell calls this event the annual reconstitution process, and it begins with evaluations in May and moves to the selection process on June 7th with the newly recons...
Motif Bio (NASDAQ: MTFB ) -48% on announcing path forward for Iclaprim. More news on: Motif Bio plc, At Home Group Inc., Cloudera, Inc., Stocks on the move, Read more ...
Shares of ADMA Biologics ( ADMA ) have lost over a third over their value over during the past three years. However, the stock has really turned around in 2019 after multiple positive developments, delivering a 92% gain during that time frame. I'd lightly glanced at ADMA Biologics in the pas...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
ADMA Biologics ( ADMA ) has racked up two big FDA wins in the past couple months. In April, it received FDA approval for Asceniv, an intravenous immune globulin (“IVIG”) drug product for the treatment of Primary Humoral Immunodeficiency Disease (“PI”). In May, the F...
RAMSEY, N.J. and BOCA RATON, Fla., May 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops spe...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...